Biotechnology company developing and commercializing first-in-class oral enzyme therapeutics for rare and severe metabolic disorders affecting the kidneys
Biotechnology company developing and commercializing first-in-class oral enzyme therapeutics for rare and severe metabolic disorders affecting the kidneys. Its non-absorbed, stable oral enzymes act in the gastrointestinal tract to break down metabolites such as oxalate and urate, reducing their levels and associated kidney disease burden.